Physician profile
Moncy Varkey
NPI 1346479029
$8,065.40
in general payments reported to CMS, 2019-2025
36 companies · $1,973 in 2025
The $1,973 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.96 · 2021: $831 · 2022: $1,337 · 2023: $2,031 · 2024: $1,880 · 2025: $1,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,883.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $920.75 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $813.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $784.69 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $632.86 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $514.07 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $486.58 | 2023-2025 | Rexulti |
| Abbott Laboratories | $347.77 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.18 | 2021-2024 | Jardiance, Synjardy |
| Pfizer INC. | $285.03 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $282.79 | 2023-2025 | Spravato |
| Eisai INC. | $281.63 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $211.97 | 2022 | |
| Currax Pharmaceuticals LLC | $199.15 | 2021-2024 | Contrave, Nexlizet, Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $186.81 | 2023-2025 | |
| Astellas Pharma US INC | $178.33 | 2021-2025 | Veozah, Myrbetriq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $167.82 | 2023-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $166.84 | 2021-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $146.78 | 2021-2024 | Capvaxive, Gardasil 9, Gardasil |
| Sanofi-Aventis U.S. LLC | $128.79 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $128.45 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $126.75 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $115.70 | 2024-2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $92.28 | 2021 | |
| Sumitomo Pharma America, INC. | $82.65 | 2023-2025 | Gemtesa |
| Amgen INC. | $78.38 | 2023-2024 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $78.35 | 2025 | Symbravo, Auvelity |
| Amarin Pharma, INC. | $60.75 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.67 | 2024-2025 | Xifaxan, Trulance |
| Edwards Lifesciences Corporation | $48.48 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kowa Pharmaceuticals America, INC. | $46.69 | 2021 | |
| Bausch Health US, LLC | $28.08 | 2022 | |
| Avinger INC. | $24.71 | 2023 | Pantheris |
| Nevro Corp. | $23.11 | 2024 | Senza |
| Esperion Therapeutics, INC. | $19.88 | 2021 | |
| Impel Pharmaceuticals INC. | $19.67 | 2022 | |
| Phadia US INC. | $14.35 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moncy Varkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.